Compare Dr. Reddys with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs NATCO PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB NATCO PHARMA DR. REDDYS LAB/
NATCO PHARMA
 
P/E (TTM) x 31.1 16.9 184.1% View Chart
P/BV x 3.6 2.7 136.4% View Chart
Dividend Yield % 0.7 1.3 51.3%  

Financials

 DR. REDDYS LAB   NATCO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
NATCO PHARMA
Mar-19
DR. REDDYS LAB/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875849 338.6%   
Low Rs1,888557 339.0%   
Sales per share (Unadj.) Rs930.2573.8 162.1%  
Earnings per share (Unadj.) Rs117.4176.0 66.7%  
Cash flow per share (Unadj.) Rs185.8198.2 93.7%  
Dividends per share (Unadj.) Rs20.006.25 320.0%  
Dividend yield (eoy) %0.80.9 94.5%  
Book value per share (Unadj.) Rs844.4842.7 100.2%  
Shares outstanding (eoy) m166.0736.50 455.0%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.61.2 209.0%   
Avg P/E ratio x20.34.0 507.8%  
P/CF ratio (eoy) x12.83.5 361.4%  
Price / Book Value ratio x2.80.8 338.1%  
Dividend payout %17.03.6 479.6%   
Avg Mkt Cap Rs m395,49625,660 1,541.3%   
No. of employees `00022.05.0 443.1%   
Total wages/salary Rs m33,5623,559 943.0%   
Avg. sales/employee Rs Th7,032.84,225.3 166.4%   
Avg. wages/employee Rs Th1,527.9718.0 212.8%   
Avg. net profit/employee Rs Th887.71,295.9 68.5%   
INCOME DATA
Net Sales Rs m154,48220,945 737.6%  
Other income Rs m3,3751,302 259.2%   
Total revenues Rs m157,85722,247 709.6%   
Gross profit Rs m31,7827,948 399.9%  
Depreciation Rs m11,348810 1,401.0%   
Interest Rs m889193 460.6%   
Profit before tax Rs m22,9208,247 277.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8581,823 211.6%   
Profit after tax Rs m19,5006,424 303.5%  
Gross profit margin %20.637.9 54.2%  
Effective tax rate %16.822.1 76.1%   
Net profit margin %12.630.7 41.2%  
BALANCE SHEET DATA
Current assets Rs m111,10123,472 473.3%   
Current liabilities Rs m58,9737,287 809.3%   
Net working cap to sales %33.777.3 43.7%  
Current ratio x1.93.2 58.5%  
Inventory Days Days7992 86.1%  
Debtors Days Days9488 106.8%  
Net fixed assets Rs m101,24518,648 542.9%   
Share capital Rs m830365 227.4%   
"Free" reserves Rs m139,40634,525 403.8%   
Net worth Rs m140,23630,760 455.9%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65643,031 522.1%  
Interest coverage x26.843.7 61.2%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.5 141.3%   
Return on assets %9.115.4 59.0%  
Return on equity %13.920.9 66.6%  
Return on capital %14.927.4 54.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67311,536 768.7%   
Fx outflow Rs m19,1042,939 650.0%   
Net fx Rs m69,5698,597 809.2%   
CASH FLOW
From Operations Rs m28,7046,688 429.2%  
From Investments Rs m-7,727-6,122 126.2%  
From Financial Activity Rs m-21,326-509 4,189.8%  
Net Cashflow Rs m-31466 -475.8%  

Share Holding

Indian Promoters % 25.5 52.0 49.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 5.4 7.8 68.9%  
FIIs % 35.3 16.6 212.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 26.0 58.8%  
Shareholders   75,885 25,395 298.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   UNICHEM LAB  VENUS REMEDIES  IPCA LABS  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Fall; Kotak Mahindra Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India are presently trading deep in the red. Benchmark indices extended losses, tracking weak global cues as markets sentiments turned negative.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 1, 2020 01:37 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS